Short Wave Pharma
Psilocybin-based Products for Treatment of Mental Health Disorders
Company Overview
Snapshot
Founded in January 2021 by Rivki Stern Youdkevich, Stephen Murphy, and Nadya Lisovoder, Short Wave Pharma operates with 1–10 employees. The company is currently in the Pre-Funding stage and is focused on advancing its psilocybin-based therapies. A key milestone occurred in August 2022 when Short Wave Pharma signed a clinical trial agreement with the Sheba Fund for Health Services and Research to study psilocybin-assisted psychotherapy for anorexia nervosa.
Business overview
Short Wave Pharma is a biopharmaceutical company specializing in the development of novel formulations of psilocybin and other active pharmaceutical ingredients (APIs). The company focuses on creating customized delivery methods for patients suffering from mental health disorders, neurodegenerative diseases, and chronic pain. Operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, Short Wave Pharma is engaged in drug discovery and development, with a particular emphasis on biologicals and drug delivery systems.
Strategic signal
In August 2022, Short Wave Pharma entered a clinical trial agreement with the Sheba Fund for Health Services and Research to investigate psilocybin-assisted psychotherapy for anorexia nervosa. This collaboration is significant as it marks the first such trial in Israel, indicating a pioneering step in the application of psychedelic compounds for severe eating disorders. For investors, this signals Short Wave Pharma's commitment to clinical validation and its potential to establish a leadership position in the emerging field of psychedelic-based therapeutics.
Log in to access full profile ›Company Intelligence Q&A
- What is Short Wave Pharma's primary focus?
- Short Wave Pharma is a biopharmaceutical company developing novel formulations of psilocybin and additional APIs, along with customized delivery methods, for patients living with mental health disorders, neurodegenerative diseases, and chronic pain.
- When was Short Wave Pharma founded and by whom?
- Short Wave Pharma was founded in January 2021 by Rivki Stern Youdkevich, Stephen Murphy, and Nadya Lisovoder.
- What significant clinical development did Short Wave Pharma announce?
- In August 2022, Short Wave Pharma signed a clinical trial agreement with the Sheba Fund for Health Services and Research to study the safety and feasibility of psilocybin-assisted psychotherapy for the treatment of anorexia nervosa. This trial is the first of its kind in Israel.
- What is the current employee size of Short Wave Pharma?
- Short Wave Pharma currently has 1–10 employees.
- What is Short Wave Pharma's role in the clinical trial for anorexia nervosa?
- Short Wave Pharma will be the exclusive commercial partner for the clinical trial, which will investigate its patent-pending psychedelic compositions and delivery methods for anorexia nervosa.